ClinicalTrials.gg
CompletedNCT05206201Updated Jul 11, 2022

A Study Of Zy-19489 Administered Via Oral Route To Investigate The Safety, Tolerability And Pharmacokinetics In Healthy Adult Human Subjects

A Phase 1 interventional study of ZY19489 Capsule and Placebo Capsule in Malaria, sponsored by Zydus Lifesciences Limited. Completed at 1 site in India. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-11.

Sponsored by Zydus Lifesciences Limited · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Malaria with a site in India — 1 open to participants now, 1 under way, none of them phase 3. Malaria · India.

Started
2021
the only one that year
Phase 1
Only one
of the 10
Registered
8th of 10
by date
Lead sponsor
1 of 10
Zydus Lifesciences Limited

Among the 10 studies in Malaria with a site in India, this one is the only one that started in 2021, is the only one in phase 1, and was the 8th registered.

Malaria

1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

1 of the 10 studies in Malaria with a site in India is open now. Recruiting first, the newest first:

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Malaria with a site in India, or all of them as a file.
02

Study summary

A Randomized, Double Blind, Parallel, Placebo-Control, Study Of ZY-19489 Administered Via Oral Route To Investigate The Safety, Tolerability And Pharmacokinetics In Healthy Adult Human Subjects aged between 18-55 years old (Both Inclusive).

Read the detailed description

Study will conduct in two parts. In Part 1; single cohort of 8 subjects. Subjects will be enrolled within a 28 day screening period to ensure subjects meet all the inclusion criteria and none of the exclusion criteria. Subjects will be randomized in a ratio of 6:2 to receive single dose of ZY-19489 or placebo orally after an overnight fast of at least 10 hours.

In Part 2: study each cohort containing eight subjects will be given either a ZY19489 capsule or placebo for three consecutive days. Total three cohorts are planned in this study. Dose escalation will be performed for subsequent cohorts.

03

Conditions studied

  • Malaria

Browse trials for

Keywords

  • Malaria
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female (non-pregnant, non-lactating) aged 18 to 55 years inclusive who will be contactable and available for the duration of the trial and up to 2 weeks following the End of Study visit.
  2. Total body weight greater than or equal to 50 kg, and a (BMI) within the range of 18.5 to 30.0 kg/m2 (Both inclusive). BMI is an estimate of body weight adjusted for height. It is calculated by dividing the weight in kilograms by the square of the height in meters.
  3. Certified as healthy by a comprehensive clinical assessment (detailed medical history, complete physical examination and special investigations).
  4. Screening vital signs:

    Systolic blood pressure (SBP) - 90-140 mmHg, Diastolic blood pressure (DBP) - 60-90 mmHg, Heart rate (HR) 60-90 bpm.

  5. ≤450 ms, PR interval ≤220 ms.
  6. Female subjects with history of sterility or at least 1 year menopause or use of long acting non hormonal measures (e.g., intrauterine device) and be willing and able to continue contraception for 90 days after administration of study treatment.
  7. Male subjects must agree to use adequate contraception methods during the study and be willing and able to continue contraception for 90 days after administration of study treatment.
  8. Completion of the written process prior to undertaking any study related procedure.
  9. Must be willing and able to communicate and participate in the whole study.

Exclusion criteria

Exclusion Criteria:

  1. Haematology, clinical chemistry or urinalysis results at screening that are outside of clinically acceptable laboratory ranges, and are considered by the Investigator.
  2. Participation in any product study within the 12 weeks preceding IMP administration.
  3. History or presence of diagnosed (by an allergist/immunologist) or treated (by a physician) food or known drug allergies, or history of anaphylaxis or other severe allergic reactions. Subjects with seasonal allergies/hay fever or allergy to animals or house dust mite that are untreated and asymptomatic can be enrolled in the study based on Investigator's discretion.
  4. History of convulsion (including intravenous drug or vaccine-induced episodes). A medical history of a single febrile convulsion during childhood is not an exclusion criterion.
  5. Presence of current or suspected serious chronic diseases such as cardiac or disease ( or other immuno-deficiencies), insulin-dependent and non-insulin dependent diabetes, progressive neurological disease, severe malnutrition, acute or progressive hepatic disease, acute or progressive renal disease, porphyria, psoriasis, rheumatoid arthritis, asthma (excluding childhood asthma, or mild asthma with preventative asthma medication required less than monthly), epilepsy, or obsessive-compulsive disorder.
  6. History of of any organ system treated or untreated, within 5 years of screening, regardless of whether there is evidence of local recurrence or .
  7. Subjects with history of schizophrenia, bi-polar disease, psychoses, disorders requiring lithium, attempted or planned suicide, or any other severe (disabling) chronic psychiatric diagnosis.
  8. Subjects who have received psychiatric medications within 1 year prior to enrolment, or who have been hospitalized within 5 years prior to enrolment for either a psychiatric illness or due to danger to self or others.
  9. History of more than one previous episode of major depression, any previous single episode of major depression lasting for or requiring treatment for more than 6 months, or any episode of major depression during the 5 years preceding screening.
  10. History of recurrent headache (e.g. tension-type, cluster or migraine) with a frequency of ≥2 episodes per month on average and/or severe enough to require medical therapy, during the 5 years preceding screening.
  11. Presence of clinically significant infectious disease or fever (e.g. sublingual temperature ≥38.5°C) within the 14 days prior to enrollment.
  12. Evidence of acute illness within the 4 weeks prior to screening that the Investigator deems may compromise subject safety.
  13. Significant inter-current disease of any type, in particular liver, renal, cardiac, pulmonary, neurologic, gastrointestinal, rheumatologic, or autoimmune disease by history, physical examination, and/or laboratory studies including urinalysis.
  14. Subject has a clinically significant disease or any condition or disease that might affect drug absorption, distribution or excretion (e.g. gastrectomy, diarrhoea).
  15. Blood donation of any volume within 1 month before IMP administration, or participation in any research study involving blood sampling (more than 450 mL/unit of blood), or blood donation to blood bank during the 12 weeks prior to IMP administration.
  16. Medical requirement for intravenous immunoglobulin or blood transfusions within 3 months prior to enrollment.
  17. History or presence of alcohol abuse (alcohol consumption more than 40 g/4 units/4 standard drinks per day), or drug habituation, or any prior intravenous usage of an illicit substance in past one year.
  18. Tobacco use of more than 5 cigarettes or equivalent per day since last one year, and unable to stop smoking for the duration of the clinical unit confinement.
  19. Female subject who is breastfeeding or currently pregnant or found positive on pregnancy test.

    Interfering substances

  20. Any vaccination within the last 28 days and planned vaccination till final study visit.
  21. Any , anti-inflammatory drugs (excluding commonly used over-thecounter anti-inflammatory drugs such as ibuprofen, acetylsalicylic acid, diclofenac), immunomodulators or anticoagulants within the past 3 months. Any subject currently receiving or having previously received therapy (including systemic steroids, adrenocorticotrophic hormone or inhaled steroids) at a dose or duration potentially associated with hypothalamic-pituitary-adrenal axis suppression within the past year.
  22. Ingestion of any poppy seeds within the 24 hours prior to screening
  23. Consumption of beverages or food containing xanthine bases including Red Bull, chocolate, coffee etc. from 48 hours prior to enrollment.
  24. Unwillingness to abstain from consumption of grapefruit or Seville oranges from 7 days prior to enrollment until the end of study.
  25. Use of prescription drugs (excluding ) or non-prescription drugs or herbal supplements (such as St John's Wort), within 14 days or 5 half-lives (whichever is longer) prior to IMP dosing. Limited use of other non-prescription medications or dietary supplements, not believed to affect subject safety or the overall results of the study, may be permitted on a case-by- case basis following approval by the Sponsor in consultation with the Investigator. Subjects are requested to refrain from taking non-approved concomitant medications from recruitment until the conclusion of the study.
  26. Any subject who, in the judgment of the Investigator, is likely to be non-compliant during the study, or is unable to cooperate because of a language problem or poor mental development.
  27. Any subject who is the Principal Investigator or any sub-Investigator, research assistant, pharmacist, study coordinator, or other staff thereof, directly involved in conducting the study.
  28. Any subject without a good peripheral venous access.
  29. Positive result on any of the following tests: surface antigen (HBs Ag), anti- virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti-HIV2 Ab).
  30. Positive urine drug test.
  31. Positive urine alcohol/breath alcohol test.
  32. The history or presence of any of the following cardiac conditions: known structural cardiac abnormalities; family history of long syndrome; cardiac syncope or recurrent, idiopathic syncope; exercise related clinically significant cardiac events.

    • Any clinically important abnormalities in rhythm, conduction or morphology of resting that may interfere with the interpretation of QTc interval changes. This includes subjects with any of the following (at screening):
    • Sinus node dysfunction.
    • Complete bundle branch block.
    • Abnormal T wave morphology.
    • Any other ECG abnormalities in the standard 12-lead ECG in the opinion of the Investigator will interfere with the ECG analysis.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    ZY19489 Capsule

    Experimental study drug

    Drug: ZY19489 Capsule

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo Capsule

Interventions

  • DrugZY19489 Capsule

    Two part study with single and multiple dose

  • DrugPlacebo Capsule

    Two part study with single and multiple dose

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse event of ZY-19489 administered to healthy subjects.

    Common Terminology Criteria for Adverse Event (CTCAE) (Version 5.0 or higher) system will be used for reporting and grading

    Time frame: For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30

Secondary outcomes

  1. Area under the curve from the time of dosing to the last measurable concentration (AUC0-t)

    Estimation of ZY-19489 and its metabolite ZY-20486

    Time frame: For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30

  2. Cmax

    Estimation of ZY-19489 and its metabolite ZY-20486

    Time frame: For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30

  3. To assess the effect of ZY-19489/ZY-20486on the QTc interval (concentration/QTc modelling).

    • Difference between baseline corrected QTc following placebo and baseline corrected QTc following ZY-19489

    Time frame: For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30

  4. AUC0-∞

    Estimation of ZY-19489 and its metabolite ZY-20486

    Time frame: For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30

  5. Tmax

    Estimation of ZY-19489 and its metabolite ZY-20486

    Time frame: For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30

  6. T1/2

    Estimation of ZY-19489 and its metabolite ZY-20486

    Time frame: For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30

  7. CL/F

    Estimation of ZY-19489 and its metabolite ZY-20486

    Time frame: For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30

  8. VZ/F

    Estimation of ZY-19489 and its metabolite ZY-20486

    Time frame: For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30

  9. λ

    Estimation of ZY-19489 and its metabolite ZY-20486

    Time frame: For Part 1 : Baseline to Day 28 and For Part 2 : Baseline to Day 30

  10. AUC0-24

    AUC0-24 after first dose on Day 0 will be calculated with PK samples on Day 01. AUC0-24 after third dose on Day 2 will be calculated with PK samples on Day 03

    Time frame: For Part 2 : Baseline to Day 30

  11. Accumulation Index

    Estimation of ZY-19489 and its metabolite ZY-20486

    Time frame: For Part 2 : Baseline to Day 30

  12. Rac(AUC)

    Estimation of ZY-19489 and its metabolite ZY-20486

    Time frame: For Part 2 : Baseline to Day 30

  13. Rac(Cmax)

    Estimation of ZY-19489 and its metabolite ZY-20486

    Time frame: For Part 2 : Baseline to Day 30

07

Study locations

1 site
  • Zydus Research Centre
    Ahmedabad, Gujarat 382213, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Jan 2022, 4 months.

Of 29 industry-sponsored phase 1 interventional studies under Malaria, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 4 months is below that.

Counting every sponsor, half of 93 studies reached it within 13 months; a quarter within 7 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2021
First posted
Jan 25, 2022
StartActual
Aug 25, 2021
Primary completionActual
Jan 21, 2022
CompletionActual
Jan 21, 2022
Last update
Jul 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05206201
Responsible party
Sponsor
First posted
Jan 25, 2022
Start date
Aug 25, 2021
Primary completion
Jan 21, 2022
Completion
Jan 21, 2022
Last update
Jul 11, 2022

Study contacts

Dr Deven Parmar, MD
study chair · Zydus Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion